Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03383575
Title Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

myelodysplastic syndrome

chronic myelomonocytic leukemia

Therapies

Azacitidine + Enasidenib

Enasidenib

Age Groups: adult | senior | child
Covered Countries USA

Facility Status City State Zip Country Details
Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore Maryland 21287 United States Details
Cleveland Clinic Foundation Cleveland Ohio 44195 United States Details
M D Anderson Cancer Center Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field